BioGenomics
BioGenomics Limited is a biopharmaceutical company focused on diabetes and cancer biopharmaceuticals. It aims to increase access to life-saving biopharmaceuticals through innovative technologies, comprehensive product ranges, and state-of-the-art manufacturing facilities. The company is committed to indigenous technology, international clinical standards, and high-quality biosimilar products. With a strong research and development center and multiple manufacturing facilities, BioGenomics is dedicated to delivering impactful healthcare solutions globally.
Industries
Nr. of Employees
medium (51-250)
BioGenomics
First Floor, Kothari Compound, Opposite Tiku-Ji-ni-Wadi, Thane (West), Maharashtra, India – 400610
Patents
Products
Insulin aspart (rapid-acting insulin analogue)
Rapid-acting insulin analogue under biosimilar development for treatment of type 1 and type 2 diabetes.
Insulin aspart mix (rapid + intermediate acting combination)
Combination formulation containing rapid-acting insulin and intermediate-acting component for diabetes management.
Insulin glargine (long-acting insulin analogue)
Long-acting insulin analogue formulation under development for basal insulin therapy in type 1 and type 2 diabetes.
Insulin lispro (rapid-acting insulin analogue)
Rapid-acting insulin analogue under development for treatment of type 1 and type 2 diabetes.
Insulin degludec (ultra long-acting insulin analogue)
Ultra long-acting insulin analogue under development for prolonged basal glycemic control.
GLP-1 analogues and combination therapies (liraglutide, tirzepatide, exenatide)
GLP-1 and dual-agonist peptide therapeutics and combinations with insulin under development for type 2 diabetes and metabolic indications.
Insulin aspart (rapid-acting insulin analogue)
Rapid-acting insulin analogue under biosimilar development for treatment of type 1 and type 2 diabetes.
Insulin aspart mix (rapid + intermediate acting combination)
Combination formulation containing rapid-acting insulin and intermediate-acting component for diabetes management.
Insulin glargine (long-acting insulin analogue)
Long-acting insulin analogue formulation under development for basal insulin therapy in type 1 and type 2 diabetes.
Insulin lispro (rapid-acting insulin analogue)
Rapid-acting insulin analogue under development for treatment of type 1 and type 2 diabetes.
Insulin degludec (ultra long-acting insulin analogue)
Ultra long-acting insulin analogue under development for prolonged basal glycemic control.
GLP-1 analogues and combination therapies (liraglutide, tirzepatide, exenatide)
GLP-1 and dual-agonist peptide therapeutics and combinations with insulin under development for type 2 diabetes and metabolic indications.
Services
End-to-end R&D support from cell-line and process development through scale-up to drug-substance and drug-product readiness for clinical supply.
Analytical method development and characterization including SPR, LC-MS/MS-Q-TOF, sequencing and gene-expression assays to support biosimilarity and release testing.
Primary packaging and fill–finish for vials, cartridges and pre-filled syringes with combi fill–finish lines and packaging equipment.
Design and operational execution of clinical studies compliant with GCP/EMA standards to establish biosimilarity, immunogenicity and clinical efficacy.
End-to-end R&D support from cell-line and process development through scale-up to drug-substance and drug-product readiness for clinical supply.
Analytical method development and characterization including SPR, LC-MS/MS-Q-TOF, sequencing and gene-expression assays to support biosimilarity and release testing.
Primary packaging and fill–finish for vials, cartridges and pre-filled syringes with combi fill–finish lines and packaging equipment.
Design and operational execution of clinical studies compliant with GCP/EMA standards to establish biosimilarity, immunogenicity and clinical efficacy.
Expertise Areas
- Biosimilar development
- Bioprocessing and fermentation scale-up
- Downstream protein refolding and purification
- Fill–finish manufacturing for parenteral biologics
Key Technologies
- Large-scale fermentation (up to 5000 L reported)
- Downstream chromatography and protein refolding
- Lyophilization (freeze-drying) for biologics
- Combi fill–finish for vials, cartridges and pre-filled syringes
News & Updates
Puducherry Manufacturing Plant Upgrade
Capacity enhancement underway, with WHO-GMP approval and EU-GMP compliance, expected post EU filing in 2025.
Sanand Facility Ahmedabad
New biopharmaceutical manufacturing facility for insulin and analogs, designed for global supply.
Oman Formulation and Fill + Finish Plant
New plant with capacity of 20 million cartridges, serving MENA and other markets.
Pipeline Developments
Development of biosimilar insulins, GLP-1 analogs, and monoclonal antibodies, with ongoing clinical trials and approvals.
Puducherry Manufacturing Plant Upgrade
Capacity enhancement underway, with WHO-GMP approval and EU-GMP compliance, expected post EU filing in 2025.
Sanand Facility Ahmedabad
New biopharmaceutical manufacturing facility for insulin and analogs, designed for global supply.
Oman Formulation and Fill + Finish Plant
New plant with capacity of 20 million cartridges, serving MENA and other markets.
Pipeline Developments
Development of biosimilar insulins, GLP-1 analogs, and monoclonal antibodies, with ongoing clinical trials and approvals.